Cohance Lifesciences Ltd (COHANCE)
₹447.35
Mkt cap
₹17,469 Cr
P/E ratio
162.00
P/B
4.39
Div yield
0.00%
ROE
4.89%
ROCE
5.81%
EPS (TTM)
₹2.76
Book value
₹102
52W range
280–1,020
Sector
Healthcare
Price history
Previous close
Cohance Lifesciences is a Hyderabad-based CDMO operating across pharmaceutical development, manufacturing, APIs, formulations and specialty chemicals. The company states that it features among the Top 20 CDMOs globally; its Pharma CDMO business works with 19 of the top 20 global innovators, while the API portfolio ranks among the top three suppliers in 8 of its top 10 molecules. [1] [2]
NSE COHANCEBSE 543064
Health check
Mixed
ValuationExpensive
ProfitabilityWeak
GrowthHigh
TechnicalsBullish
52-week range
−56.13% from high₹447
₹280+59.82% from low₹1,020
Current
₹447.35
Prev close
₹456.00
Day
−1.90%
Price performance
1D
−1.90%
1W
−1.89%
1M
+0.36%
3M
+3.58%
6M
+50.04%
1Y
−50.25%
YTD
−13.69%
Financials
Revenue, profit & margin
P/E ratio
162.0×
COHANCE is 377% above the sector median of 34.0×
COHANCE162.0×
Sector median34.0×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 348 | 231 | 220 | 253 | 488 | 604 | 676 | 840 | 549 | 556 | 545 | 619 | 422 | |
| Expenses | 181 | 133 | 154 | 180 | 363 | 398 | 439 | 611 | 437 | 435 | 449 | 520 | 421 | |
| Operating Profit | 167 | 98 | 66 | 73 | 125 | 205 | 237 | 229 | 112 | 121 | 95 | 99 | 1 | |
| OPM % | 48% | 42% | 30% | 29% | 26% | 34% | 35% | 27% | 20% | 22% | 18% | 16% | 0.3% | |
| Other Income | 11 | 20 | 14 | 17 | 19 | 16 | 22 | -4 | 6 | 16 | 1 | -18 | 12 | |
| Interest | 1 | 0 | 2 | 2 | 10 | 10 | 11 | 10 | 10 | 9 | 9 | 9 | 7 | |
| Depreciation | 13 | 12 | 13 | 17 | 31 | 38 | 44 | 54 | 45 | 44 | 47 | 51 | 50 | |
| Profit before tax | 164 | 105 | 65 | 71 | 103 | 174 | 205 | 161 | 63 | 84 | 41 | 20 | -43 | |
| Tax % | 26% | 25% | 29% | 25% | 27% | 21% | 25% | 27% | 26% | 21% | 29% | 58% | 5% | |
| Net Profit | 121 | 80 | 47 | 53 | 75 | 138 | 153 | 117 | 46 | 66 | 29 | 8 | -45 | |
| EPS in Rs | 4.74 | 3.13 | 1.84 | 2.10 | 2.96 | 5.44 | 6.01 | 4.73 | 1.28 | 1.94 | 0.96 | 0.51 | -0.63 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −1.79% · closed higher next day 10 of last 23
| Q1FY24 | Q2FY24 | Q3FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26† | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 8 Aug '23◦ | 10 Nov '23◦ | 6 Feb '24◦ | 9 Aug '24◦ | 13 Nov '24◦ | 13 Feb '25◦ | 28 May '25◦ | 13 Aug '25◦ | 12 Nov '25 | 12 Feb '26◦ | 12 May '26◦ | 5 Aug '26◦ |
| Earnings day | +0.59% | −0.47% | +1.16% | +4.69% | +0.98% | −2.71% | −3.81% | −7.32% | −8.81% | −10.02% | −5.85% | +2.20% |
| +1 day | +2.59% | −1.81% | +3.32% | +3.52% | +1.48% | −0.06% | −5.51% | −9.00% | −10.78% | −12.59% | −8.14% | +3.80% |
| +5 days | +6.38% | +3.33% | +6.68% | +0.19% | +2.50% | +9.50% | −4.07% | −10.28% | −15.66% | −12.93% | −13.31% | +3.43% |
| +15 days | +4.72% | +14.74% | +4.63% | +12.58% | +3.46% | +3.26% | −10.65% | +2.73% | −20.41% | −19.44% | −12.25% | +5.72% |
| +30 days | +8.23% | +20.23% | +2.71% | +21.96% | −9.79% | −2.27% | −10.18% | −11.12% | −22.11% | −11.06% | −5.49% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202657.49%Promoter
Promoters57.49%
FIIs6.50%0.91
DIIs20.09%1.70
Public15.92%0.81
Government0.01%
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,899.00 | 36.07 | 4,55,634 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,100.00 | 81.09 | 2,41,576 | 0.33% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,857.00 | 82.80 | 1,84,745 | 0.78% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| CIPLA | ₹1,385.00 | 31.26 | 1,11,888 | 0.94% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| ZYDUSLIFE | ₹1,120.00 | 22.95 | 1,11,720 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| LAURUSLABS | ₹1,840.00 | 90.93 | 99,417 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,110.00 | 16.20 | 96,483 | 0.85% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| COHANCE | ₹456.60 | 162.25 | 17,469 | 0.00% | −45 | −144.15% | 422 | −23.13% | 5.81% |
| Median: 158 Co. | ₹421.50 | 33.96 | 2,277 | 0.08% | 13 | +30.25% | 164 | +18.67% | 14.96% |
Filings
Annual reports7
Concall transcripts66
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025TranscriptNov 2025TranscriptAug 2025PPTAug 2025TranscriptJun 2025PPTJun 2025RECJun 2025TranscriptFeb 2025PPTFeb 2025RECFeb 2025PPTJan 2025TranscriptDec 2024PPTDec 2024TranscriptDec 2024PPTDec 2024
Credit ratings6
Announcements5
Completion Of USFDA Inspection 5 Sep - USFDA inspected Shamshabad FDF plant, 27 Aug-4 Sep 2026, and issued Form 483 with four observations.Announcement under Regulation 30 (LODR)-Press Release / Media Release 3 Sep - Cohance to invest USD 18 million in NJ Bio and Aruka Bio, completing by September 2026.Board Meeting Outcome for Outcome Of The Committee Meeting 3 Sep - Cohance will invest USD 18 million, lifting NJ Bio to 67.3% and Aruka Bio to 65%.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 27 Aug - Management will attend Ashwamedh - Elara India Dialogue 2026 in Mumbai on 1 September 2026.Announcement under Regulation 30 (LODR)-Newspaper Publication 27 Aug